Accolade — Q4 2023 Earnings Presentation
33 slides from Accolade's earnings presentation, Apr 27, 2023
Slide 1: Accolade Inc. Investor Presentation
Accolade Inc. Investor Presentation
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: The Cost of a Poor Healthcare Experience
76% of people don’t understand their available benefits or how they work 88% of workers reported extreme The Cost of a stress, compared to 16% before the onset of COVID Poor Healthcare $225.88B Experience in lost workforce productivity due to poor healthcare and preventable chronic conditions cost U
Slide 4: An imperfect system
75% of healthcare spending is on chronic health conditions* * cdc.gov An imperfect system 80% of the US lacks adequate The healthcare system is reactive access to healthcare* * goodrx.com Healthcare access is inadequate Investments alone aren’t improving the experience $29B in digital health startup
Slide 5: Accolade is Engineered to Care
Predictive Engagement Proactive Care Accolade is Engineered to Care Addressing Barriers 5
Slide 6: Engineered to Care
Engineered to Care Technology and People deliver Expert Physicians Early and Repeat Diagnosis & Treatment Review Engagement 69% Member Insights PCPs & and care Therapists Acute, Chronic recommendation & Preventive Care team interaction Ongoing data analysis and influence Registered Outcomes Member N
Slide 7: The People Behind Our Solutions
The People Behind Our Solutions Top Physicians Registered Nurses Health Assistants Extended Care Team & Medical Experts § From the top 50 U.S. § Varied experience § 66% degreed § Claims and Benefits medical schools across medical professionals Specialist, Logistics § Average experience disciplines §
Slide 8: The three pillars of Engineered to Care
The three pillars of Engineered to Care Predictive Proactive Addressing Engagement Care Barriers Going beyond standard Personalized Identify and resolve barriers engagement strategies recommendations and so members get the right to drive the right action interventions delivered by care Clinical Expe
Slide 9: Predictive Engagement
Combine verification of benefits & utilization management with Intercept members insights to inform engagement approach Engineered to Care: Predictive Identify 50% more 70%+ family engagement Engagement Outbound high-risk members earlier in the care journey Going beyond standard 95%+ engagement stra
Slide 10: Proactive Care
Engineered to Care: Proactive Care Personalized recommendations and interventions delivered by Clinical Experts 66% of members engage before seeking care Possible Clinical Member Data + Interventions = True Health ActionsTM Rank what is most impactful for each member according to their situation and
Slide 11: Addressing Barriers
Engineered to Care: Addressing Barriers Identify and resolve barriers so members get the care they need What We Do Accolade Impact Listen with empathy Good access to care Understand context Improved health literacy Identify barriers to care Confidence in care decisions 3x more likely to uncover cont
Slide 12: Delivering Value Across the Entire Healthcare Journey
Delivering Value Across the Entire Healthcare Journey Benefits Education, Utilization and Engagement Provider Selection, Care Delivery and Support Research plan options Address medical Engage in care Annual Open Receive Schedule management Benefit card bills and ongoing Enrollment appointment treatm
Slide 13: A Truly Powerful, Personalized Healthcare Platform
A Truly Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based Accolade Accolade Accolade Advocacy Expert MD Care Personalized, trusted Real-time expert Same-day access to guidance and education consultations for members virtual primary and mental for all benefits and clinic
Slide 14: Achieving Better Outcomes
Achieving Better Outcomes What we know shapes what we do Build strong Address Impact Integrate Engage whole Integrate all high-cost context/social clinical behavioral population clinical needs members early determinants relationships health § 60% of high-cost § PCP use dropped 24% § 80% of a diabeti
Slide 15: Personalized Healthcare
Personalized Healthcare Engagement cannot be solved with any single approach ACCOLADE ENGAGEMENT MODEL Benefit Intelligent Member Utilization Provider Outreach Inquiries Inbound Services Management Search 15
Slide 16: Our Engagement and Clinical Approach Drives Results
Our Engagement and Clinical Approach Drives Results % Assisted %Provider Engagement Total Contacts 25 100% 98% 94% 93% 90% 79% 20 80% 70% 62% 15 60% 52% 42% 40% 10 40% 29% 20% 20% 5 0% 0 0 - $2500 $2.5k - $10k $10k to $25k $25k to $50k $50k to $100k $100k+ Low-spend Families Middle-spend Families Hi
Slide 17: Personalized Healthcare Impact
Personalized Healthcare Impact T R U E H E A LT H T R U E H E A LT H ENGINE ACTION PLAN 4.7% lower claims costs – 60+% 93% independent validation (Aon) engagement of members follow recommended action 69% 91% 98% of members state having repeat engagement of members state Accolade Accolade positively
Slide 18: Engaging the Ecosystem
Engaging the Ecosystem Accolade helps members learn about and leverage the benefits available to them. Driving appropriate utilization of these programs is core to our value proposition.
Slide 19: Accelerating Accolade's Innovation
Accelerating Accolade’s Innovation Continuous investment in clinical transformation and operational excellence Created a Proven Launched Intelligent Launched Launched Mental Acquired 2nd.MD - Acquired PlushCare - Introduced High Touch, High Provider Matching Accolade COVID Health Integrated Expert M
Slide 20: Significantly Expanded Addressable Market $216 billion
Significantly Expanded Addressable Market $216 billion TAM 900 Customers 800+ $170B 800 Primary Care 700 600+ 600 500 $22B 400 Expert Medical Opinion 300 200 $24B 112 Navigation & Advocacy 100 54 15 20 0 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 (w M&A) 20
Slide 21: Compelling Growth Strategy
Compelling Growth Strategy Grow customer base Further penetrate our market of 30,000+ self- and fully insured employers Retain and expand Grow relationships especially through the sale of add-on services such as Virtual Primary Care and Expert Medical customer relationships Opinion Leverage machine
Slide 22: Financials
Financials 22
Slide 23: Financial Highlights
Financial Highlights Growing Customer, Solution and Channel Diversification Strong sales momentum and expansion of product suite supporting broader market capture ARR Bookings & new offerings driving substantial revenue growth 33% ARR growth FY22 to FY23; Ended FY23 with $309mm ACV PMPM recurring re
Slide 24: Strong Revenue Growth
Strong Revenue Growth Predictable, highly visible, and recurring revenue Revenue and FYE ACV Quarterly Revenue $ millions $ millions $400 Revenue ACV at FYE $363 $110 FY21 FY22 FY23 $350 $ 99 $100 $94 $310 $309 $ 88 $ 91 $300 $286 $90 $ 86 $84 $80 $73 $250 $70 $212 $60 $59 $200 $60 $170 $161 $50 $15
Slide 25: Annual Result Trends
Annual Result Trends Revenue Adjusted Gross Profit and $363 M Adjusted Gross Profit Margin $310 M $170 M $144 M $170 M $133 M $78 M $95 M $59 M $35 M 36.4% 44.6% 45.6% 46.5% 46.8% FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Adjusted EBITDA (Loss)* Adjusted Operating Expenses (as % of revenue)
Slide 26: Revenue and Customer Growth + Unit Economics Drive Path to Profitability
Revenue and Customer Growth + Unit Economics Drive Path to Profitability ~20% annual revenue growth** Revenue vs Adjusted EBITDA (Loss) as a % of Revenue* ~$500 M $410 M $363 M $310 M $170 M $133 M $77 M $95 M 0% - 3% (10)% (2-4)% (16)% (13)% (25)% (41)% (56)% FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25
Slide 27: Financial Targets and Goals (Non-GAAP)
Financial Targets and Goals (Non-GAAP) Long-Term Goals Commentary Investments in technology and offering mix projected to drive GM% Adj. Gross Margin 50-55% up P&T as Projecting to continue to increase absolute dollar investments in % of Rev. 13-17% Product & Tech at a decreasing rate Adj. As sales
Slide 28: Appendix
Accolade Appendix
Slide 29: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, and excluding stock-based compensation and severance costs. We define Adjus
Slide 30: Adjusted EBITDA (Loss) Reconciliation
Adjusted EBITDA (Loss) Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Net Loss $ (56,496) $ (51,365) $ (50,652) $ (123,124) $ (459,650) Adjusted for: Interest expense (income), net 2,374 2,925 3,724 2,905 (255) Income tax expense (benefit) 55 129 4 (5,63
Slide 31: Adjusted Gross Margin Reconciliation
Adjusted Gross Margin Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 $ 363,142 Less: Cost of revenue, excluding depreciation and (60,568) (73,685) (93,673) (169,019) (198,905) amortization Gross Profit, excl
Slide 32: Adjusted Operating Expense Reconciliation
Adjusted Operating Expense Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2019 2020 2021 2022 2023 Revenue $ 94,811 $ 132,507 $ 170,358 $ 310,021 $ 363,142 Operating Expenses 88,220 107,026 123,462 266,727 627,751 Less: Depreciation and amortization (9,391) (8,516) (8,212) (42,6
Slide 33: Accolade
Accolade PERSONALIZED HEALTHCARE